| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways S Zhang, WC Huang, P Li, H Guo, SB Poh, SW Brady, Y Xiong, LM Tseng, ... Nature medicine 17 (4), 461-469, 2011 | 621 | 2011 |
| Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia B Li, SW Brady, X Ma, S Shen, Y Zhang, Y Li, K Szlachta, L Dong, Y Liu, ... Blood, The Journal of the American Society of Hematology 135 (1), 41-55, 2020 | 229 | 2020 |
| The genomic landscape of pediatric acute lymphoblastic leukemia SW Brady, KG Roberts, Z Gu, L Shi, S Pounds, D Pei, C Cheng, Y Dai, ... Nature genetics 54 (9), 1376-1389, 2022 | 179 | 2022 |
| Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer EL Christie, S Pattnaik, J Beach, A Copeland, N Rashoo, S Fereday, ... Nature communications 10 (1), 1295, 2019 | 153 | 2019 |
| Combating subclonal evolution of resistant cancer phenotypes SW Brady, JA McQuerry, Y Qiao, SR Piccolo, G Shrestha, DF Jenkins, ... Nature communications 8 (1), 1231, 2017 | 150 | 2017 |
| Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing S Newman, J Nakitandwe, CA Kesserwan, EM Azzato, DA Wheeler, ... Cancer discovery 11 (12), 3008-3027, 2021 | 140 | 2021 |
| St. Jude Cloud: a pediatric cancer genomic data-sharing ecosystem C McLeod, AM Gout, X Zhou, A Thrasher, D Rahbarinia, SW Brady, ... Cancer discovery 11 (5), 1082-1099, 2021 | 139 | 2021 |
| Pan-neuroblastoma analysis reveals age-and signature-associated driver alterations SW Brady, Y Liu, X Ma, AM Gout, K Hagiwara, X Zhou, J Wang, M Macias, ... Nature communications 11 (1), 5183, 2020 | 113 | 2020 |
| Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease–directed therapy S Jeha, J Choi, KG Roberts, D Pei, E Coustan-Smith, H Inaba, JE Rubnitz, ... Blood cancer discovery 2 (4), 326-337, 2021 | 102 | 2021 |
| Therapeutic and prognostic insights from the analysis of cancer mutational signatures SW Brady, AM Gout, J Zhang Trends in Genetics 38 (2), 194-208, 2022 | 59 | 2022 |
| Src inhibition blocks c-Myc translation and glucose metabolism to prevent the development of breast cancer S Jain, X Wang, CC Chang, C Ibarra-Drendall, H Wang, Q Zhang, ... Cancer research 75 (22), 4863-4875, 2015 | 59 | 2015 |
| Engineered 3D model of cancer stem cell enrichment and chemoresistance MRW Rashidi, P Mehta, M Bregenzer, S Raghavan, EM Fleck, EN Horst, ... Neoplasia 21 (8), 822-836, 2019 | 52 | 2019 |
| The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma M Pan, WC Wright, RH Chapple, A Zubair, M Sandhu, JE Batchelder, ... Nature communications 12 (1), 6468, 2021 | 51 | 2021 |
| The clonal evolution of metastatic osteosarcoma as shaped by cisplatin treatment SW Brady, X Ma, A Bahrami, G Satas, G Wu, S Newman, M Rusch, ... Molecular Cancer Research 17 (4), 895-906, 2019 | 51 | 2019 |
| PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition SW Brady, J Zhang, MH Tsai, D Yu Cancer biology & therapy 16 (3), 402-411, 2015 | 51 | 2015 |
| The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms JR Schwartz, J Ma, J Kamens, T Westover, MP Walsh, SW Brady, ... Nature communications 12 (1), 985, 2021 | 50 | 2021 |
| Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor SW Brady, J Zhang, D Seok, H Wang, D Yu Molecular cancer therapeutics 13 (1), 60-70, 2014 | 48 | 2014 |
| HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer DR Boulbes, ST Arold, GB Chauhan, KV Blachno, N Deng, WC Chang, ... Molecular oncology 9 (3), 586-600, 2015 | 43 | 2015 |
| Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors O Sahin, Q Wang, SW Brady, K Ellis, H Wang, CC Chang, Q Zhang, ... Cell research 24 (5), 542-559, 2014 | 36 | 2014 |
| Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia S Kimura, L Montefiori, I Iacobucci, Y Zhao, Q Gao, EM Paietta, ... Blood, The Journal of the American Society of Hematology 139 (24), 3519-3531, 2022 | 31 | 2022 |
